This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lie, A. K.W. Articles by To, L. B. Search for Related Content PubMed PubMed Citation Articles by Lie, A. K.W. Articles by To, L. B.

Peripheral Blood Stem Cells: Transplantation and Beyond

Division of Haematology, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Adelaide, Australia

Correspondence: Albert K.W. Lie, M.D., Division of Haematology, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Frome Road, Adelaide SA 5000, Australia. Telephone: 61-8-8222-3387; Fax: 61-8-8222-3538.

Peripheral blood stem cells are rapidly becoming a major source of hemopoietic stem cells for transplantation in patients with various hematological and oncological conditions. Clinical results of peripheral blood stem cell transplantation (PBSCT) have shown benefits of earlier hemopoietic recovery, lower morbidity, and greater cost-effectiveness compared with conventional bone marrow transplant. Moreover, the relative ease of obtaining large amounts of stem cells has made multicycle transplantation a viable option in the treatment of malignancies, allowing further escalation of chemotherapy dose intensity. The extension of PBSCT into the use of allogeneic and cord blood cells so far has been met with encouraging results, and the latter holds promise to increasing donor availability to patients requiring transplantation. Developments in cytokine research and ex vivo manipulation of hemopoietic stem cells are enabling new approaches to anticancer treatment involving tumor purging, immunomodulation, ex vivo expansion of stem cells and gene therapy. PBSCT may also become a therapeutic option in certain nonmalignant diseases. This review will discuss the current clinical practice and future developments in PBSCT.

Key Words. Stem cells • Peripheral blood progenitor cells • Transplantation • Chemotherapy • Hemopoietic growth factors • Apheresis

This article has been cited by other articles:

				M. Inoue, F. Koga, S. Kawakami, N. Numao, M. Sakura, T. Kobayashi, and K. Kihara False Tumor Marker Surge Evoked by Peripheral Blood Stem Cell Transplantation Oncologist, May 1, 2008; 13(5): 526 - 529. [Abstract] [Full Text] [PDF]

				T.-X. Fan, H. Hisha, T.-N. Jin, K. Sugiura, M. Inaba, G.-X. Yang, Q. Li, X.-L. Wang, C.-Y. Song, Y.-Z. Cui, et al. Induction of Tolerance in Quadruple Chimeric Mice Stem Cells, September 1, 2004; 22(5): 683 - 695. [Abstract] [Full Text] [PDF]